This week in Cardiology
Nov 16, 2026
Biatrial Versus Left Atrial Maze Ablation During Cardiac Valve Surgery for Persistent Atrial Fibrillation: The ABLATION Trial.
In rheumatic mitral valve surgery with persistent atrial fibrillation, biatrial Cox-Maze IV ablation achieved more freedom from atrial tachyarrhythmias at one year than a left atrial set, without more pacemakers.
Circulation · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: a fuller maze lesion set wins in rheumatic valve surgery, wire-free coronary physiology holds up against the pressure wire, and skipping the morning ACE inhibitor dose before surgery cuts hypotension.
Welcome to This Week in Cardiology. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
Circulation published the ABLATION trial, led by Li and colleagues [1]. This multicentre, randomised, single-blind trial enrolled 323 patients with persistent or long-standing persistent atrial fibrillation undergoing rheumatic mitral valve surgery. Patients were assigned to a complete biatrial Cox-Maze IV procedure or to a left-sided maze lesion set. Surgeons were trained and certified beforehand, and every procedure was video recorded and centrally reviewed. At twelve months, about 79 percent of patients in the biatrial group were free from atrial tachyarrhythmias off antiarrhythmic drugs, against about 69 percent in the left atrial group. That adjusted difference of roughly eleven points was statistically significant. Freedom from permanent pacemaker implantation was 97 percent with the biatrial approach and 98 percent with the left atrial set, which met the prespecified noninferiority margin. The main limitation is the population. Patients were mostly women, relatively young, with large left atria and rheumatic disease, so the result may not carry over to degenerative valve disease or other surgical settings. Follow-up is also limited to one year. The trial gives randomised evidence on a lesion-set question that had largely been argued from observational series, and in this group it favours the biatrial set.
From the Journal of the American College of Cardiology, the LIPSIA-STRATEGY trial, led by Majunke [2], randomised 1,053 patients with acute or chronic coronary syndromes and at least one intermediate stenosis at eight German centres. Revascularisation was guided either by angiography-derived vessel fractional flow reserve or by pressure wire fractional flow reserve. At one year, major adverse cardiac events, meaning cardiac death, myocardial infarction or unplanned revascularisation, occurred in 3 percent of the angiography-derived group and about 4 percent of the wire group. That met the prespecified absolute noninferiority margin of 3.5 percentage points. The limitation is substantial, and the authors state it themselves. Event rates were lower than expected, so the absolute margin was looser on a relative scale than intended. In a post hoc analysis using the relative margin implied by the original assumptions, noninferiority was not met in the primary population, although it was met per protocol. The angiography-derived approach also classified more lesions as significant and led to more revascularisation, about 41 percent against 36 percent. One-year event rates cannot show whether that extra revascularisation helps. The trial adds randomised data to an inconsistent evidence base, with a result that depends on how the margin is framed.
The BMJ published a multicentre, randomised, double-blind, placebo-controlled trial led by Yang [3] across five tertiary hospitals in China. It enrolled 2036 patients aged 60 to 80 who were taking an ACE inhibitor or angiotensin receptor blocker and were scheduled for non-cardiac surgery under general anaesthesia. On the morning of surgery, patients took either their usual drug or an identical placebo capsule. Perioperative hypotension occurred in about 31 percent of patients given placebo against about 46 percent of patients who took their usual drug, an absolute reduction of about fourteen points. Vasopressor use also fell, and episodes of hypotension were slightly shorter. On the cardiology-relevant outcomes, major cardiocerebral events at thirty days did not differ significantly between groups, and neither did mortality, neurocognitive disorders or postoperative hypotension. The main limitation is that hypotension is a physiological endpoint, and the trial was not built to show that avoiding it prevents myocardial injury or death. It was also confined to older Chinese patients at tertiary centres. Its strength is design: blinded, placebo-controlled allocation removes the bias of open-label comparisons, and the authors describe the evidence as high certainty for this population.
Now, four in brief.
Three papers in the Journal of the American College of Cardiology address left atrial appendage closure. ASAP-TOO, led by Reddy [4], randomised 481 patients deemed unsuitable for oral anticoagulation to a Watchman device or to single antiplatelet therapy or no therapy. It stopped early because of slow accrual, with heavy withdrawal in the control arm and only 31 of 101 planned efficacy events. Ischemic stroke or systemic embolism at up to five years occurred in about 8 percent with closure and 11 percent with control, a difference that was not statistically significant. Major bleeding was numerically higher with closure, concentrated in the first three months on mandated antiplatelet therapy. The authors call the findings exploratory.
An individual participant data meta-analysis by Skurk [5] pooled CLOSURE-AF and PRAGUE-17, covering 1,290 patients at high risk of both stroke and bleeding. Closure did not differ significantly from contemporary medical therapy on the composite of stroke, systemic embolism or cardiovascular death, at about 22 percent against 21 percent, or on overall major bleeding. Bleeding was higher with closure at one year, by about three points, and by three years the cumulative difference had narrowed without any bleeding benefit emerging. With only two trials and limited long-term follow-up, the later estimates are imprecise. Like ASAP-TOO, it does not show a clear advantage for closure.
A JACC Evidence Review by Bikdeli [6] argues against pooling the closure trials into one estimate. It finds that OPTION, CLOSURE-AF, CHAMPION-AF and earlier trials differed in patient phenotype, comparator, device generation, antithrombotic regimen, endpoint construction and follow-up. It also flags methodological problems, including bleeding events inside noninferiority composites and exclusion of periprocedural bleeding from some safety endpoints. The authors conclude that anticoagulation remains first-line for most eligible patients, with closure a reasonable option when long-term anticoagulation is unsafe or unsustainable, and they note that randomised evidence in that group is limited. This expert synthesis sits in some tension with the pooling approach of the meta-analysis.
Also in JACC, ten-year follow-up of DECISION-CTO, led by Kim [7], from 19 centres in five Asian countries. Among 804 patients with a chronic total occlusion randomised to an initial strategy of occlusion PCI or no occlusion PCI, both with guideline-directed medical therapy, the composite of death, myocardial infarction, stroke or any revascularisation occurred in about 34 percent against 37 percent, not a significant difference. Event-free survival time was almost identical, and all-cause death did not differ significantly. Follow-up was complete in about 86 percent of patients, and the authors note that the wide uncertainty precludes firm conclusions about benefit or harm.
Three quick signals.
In JAMA Cardiology, a prespecified secondary analysis of the SOUL trial by Marx [8] counted first and subsequent major adverse cardiovascular events in 9650 people with type 2 diabetes and atherosclerotic disease or chronic kidney disease. Oral semaglutide reduced total events by about 14 percent versus placebo. This is a secondary analysis of an already positive trial, and discontinuation for adverse events was higher with semaglutide.
Also in JAMA Cardiology, Chan and colleagues [9] used an artificial intelligence algorithm to measure the coronary fat attenuation index on noncontrast calcium scans, with external validation in more than 19,000 people. The score improved prediction of cardiovascular death beyond calcium score, most strongly at a calcium score of zero. These are observational prognostic data, without evidence that acting on the score changes outcomes.
In the European Heart Journal, Ohle and colleagues [10] derived a seven-variable bedside rule to exclude acute aortic syndrome without further testing. In external validation it missed no cases, and in the low-prevalence DAShED cohort it ruled out just over a third of patients. Specificity was modest, the derivation was retrospective, and the authors call for prospective validation.
Stepping back across this week's papers, several trials met their prespecified criteria on margins or composites that the authors themselves treat with caution. Lower than expected event rates, early termination and incomplete long-term follow-up left wide uncertainty in the device and revascularisation comparisons, and a structured review questions whether the appendage closure trials can be pooled at all. The firmest evidence came from blinded trials with common, clearly defined outcomes, while hard clinical endpoints remain underpowered across most comparisons.
If you only have time for one paper this week, make it the ABLATION trial [1]. It provides randomised, centrally audited evidence on a lesion-set question that guidelines had left open, at least for patients with rheumatic valve disease.
That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Cardiology every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?